Organisation paid for research Program year 2025 Source: CMS Open Payments

Heart Center Research

Neither a doctor nor a teaching hospital

Research payments

$1,793,478

125 payments

Through program year 2025, Heart Center Research is reported as receiving $1,793,478 in research payments, across 125 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $678,121 12
2024 Research $457,832 10
2023 Research $334,233 11
2022 Research $44,206 17
2021 Research $102,979 25
2020 Research $52,881 24
2019 Research $123,227 26

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $1,241,640 22 payments
  2. Atricure, Inc. $299,523 13 payments
  3. CSL Behring $225,016 89 payments
  4. AstraZeneca Pharmaceuticals LP $27,300 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Hps-4/Timi 65/Orion-4: A Double-Blind Randomized Placebo-Controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease $905,390 6 payments
  2. A Multicenter Patient Registry for Outcomes From Comprehensive Ablation Treatments of Atrial Arrhythmias $217,740 4 payments
  3. A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome $133,338 65 payments
  4. A multi-center, randomized, double-blind, placebo-controlled, parallel-group Phase IIIb study evaluating the effect of inclisiran on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diagnosis of non-obstructive coronary artery disease without previous cardiovascular events (VICTORION-PLAQUE) $109,182 3 payments
  5. Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II $91,678 24 payments
  6. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase Iiib Study Evaluating the Effect of Inclisiran on Atherosclerotic Plaque Progression Assessed By Coronary Computed Tomography Angiography (Ccta) in Participants With A Diag $68,522 3 payments
  7. Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial $43,600 2 payments
  8. Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial $37,983 6 payments
  9. Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION) $34,156 2 payments
  10. Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor Arni Versus Ace Inhibitor Trial to Determine Impact on Serious Events After Myocardial Infarction Paradise Mi $33,181 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record